Fujifilm Biotechnologies opened a new 2,000-square-meter quality control laboratory at its commercial-scale Hillerød, Denmark site, adding capacity for bioassay and virology testing. The company said Danish Medicines Agency (DKMA) approval followed an on-site inspection and that operations will begin in May 2026. The expansion includes lab ventilation and airlock systems, robotics, and an ongoing LIMS rollout to harmonize data integrity across its network. Fujifilm also tied the new QC footprint to a reported doubling of Hillerød mammalian cell culture capacity in 2024. For biopharma sponsors outsourcing manufacturing, the investment signals continued emphasis on release testing throughput and standardized QC operations as cell-based manufacturing scales.